Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PMA BUDGET FOR 1985 IS $10.3 MIL.: FIRST PROGRAM-BUDGETED PLAN CALLS FOR INCREASES TO SUPPORT GOALS FO MULTINATL. INDUSTRY; NEW MEMBERSHIP CATEGORY SET

Executive Summary

PMA's budget for fiscal 1985 (July 1, 1984 - June 30, 1985) is $10.3 mil. -- up from $9.1 mil. in the current fiscal year -- as the assn. takes on the expensive projects of defending the drug industry in public opinion forums. The assn. budget has increased about 50% since President Engman took over the operations. Outgoing assn. treasurer, John Robson (Searle Exec VP), reported that the $9.1 mil. expenditures for the fiscal year ending next month will "permit the transfer of $400,000 to rebuild the reserve fund." The assn.'s reserve fund was depleted in fiscal 1983; it now reportedly stands at about $1.2 mil. The 1985 budget, Robson reported, was the first to be developed by the assn. through a program-budgetting method. He pointed out that "the world has become more complex, so the potential range of activities in which PMA might engage is nearly infinite. The maintenance of reasonable control over future budgets will demand careful evaluation and rigid prioritization of the many activities." The assn. is instituting a 10% dues increase for 1985. Robson noted that dues have remained stable for two years; therefore, the effective increase is less than 5% a year. PMA 1984-1985 Chairman Williams commented on the budget in his annual meeting remarks: "I'm pleased that the 1984-1985 budget has been cast to support the strategic plan. It's an active budget. It's a program-driven budget. It allocates specific funds to achieve specific goals, emphasizing the multinatl. character of our industry. For example, it supports studies of the Bangladesh experience, as well as the role of pharmaceuticals in the world's poorest countries." PMA also amended its by-laws at the meeting to permit new memberships from the growing number of genetic engineering and dosage research firms. The assn. approved a new membership category, "research affiliate." The assn. also deleted the Medical Devices and Diagnostics Section. PMA cut the section staff and budget last year. The assn. further expanded the number of potential board seats to 40. The assn. previously had 33 board seats authorized. Abbott Chairman Robert Schoellhorn was selected as chairman-elect for 1984-1985. He will assume the top spot in the assn. at the next annual meeting in Boca Raton, Florida, April 14-17, 1985. Also new to the PMA hierrchy is Marion President Fred Lyons, who was elected Treasurer for 1984-1985. The new faces on the PMA board are Larry Hoff (Upjohn), Max Link (Sandoz) Duane Miller (Revlon), Hazen Richardson (DuPont), Klaus Risse (Miles), Jerry Robertson (3M), George Sella (American Cyanamid), David Sharrock (Merrell Dow), John Stafford (American Home Products), Harry Tecklenburg (P&G) and John Williford (CooperVision).Picture 1, Robert Schoellhorn PMA Chairman-elect; Picture 2, Joseph Williams PMA Chairman

Latest Headlines
See All
UsernamePublicRestriction

Register

PS006574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel